Resistant and Mutational Cells

Zev Wainberg, MD; Stanton L. Gerson, MD; and Sy Schlager, MD
Video Categories: Cancer Stem Cells and PMO Interview with the Innovator Series: Volume 11

Dr Wainberg and Dr Gerson talk about the efficacy limitations of cytotoxic chemotherapy on some cells for a variety of reasons.

June 16, 2015

The Biomarker: Melanoma

PMO is pleased to offer the department “The Biomarker” to discuss the identification of biomarkers in patients with cancer and the prognostic/predictive impact and clinical decision-making implications of that marker. This month, we focus on KIT mutations in melanoma patients. Dr Sanjiv Agarwala provides his insights on this provocative topic.

April 24, 2014

Pilot Payer-Provider Collaborations

Linda Bosserman provides insight into positive data around payer-provider collaborations